Session » Rheumatoid Arthritis - Clinical Aspects: Novel Biomarkers and Other Measurements of Disease Activity

Abstract Number: 348

Smoking Status Is Associated with Inflammatory Cytokine Profile and Disease Activity: Decreased Inflammation and Disease Improvement with Smoking Cessation?

Abstract Number: 349

Galectin-3 in the Systemic Circulation Is Increased in Newly Diagnosed Rheumatoid Arthritis and Is Associated with Anti-CCP and Bone Marrow Edema

Abstract Number: 350

Rho-Associated Protein Kinase (ROCK) Activity Is Elevated in Rheumatoid Arthritis (RA) Patients and May be Responsive to RA Therapies

Abstract Number: 351

Doctor, Will My Fatigue be Better If I’m in Remission? an Exploratory Analysis of 1284 Rheumatoid Arthritis (RA) Patients Indicates Fatigue Is the Only Aspect of Patient-Perceived Impact to Remain Significant in ACR/EULAR Boolean Remission

Abstract Number: 352

Remaining Pain in Spite of Suppressed Inflammation in Early Rheumatoid Arthritis – Long-Term Strongly Increased Risk for Widespread Pain and Fatigue

Abstract Number: 353

Sensitivity of Unique Multidimensional Health Assessment Questionnaire Items Compared to Items on Both the HAQ and MDHAQ in Patients with RA and SLE

Abstract Number: 354

Increased Vascular Wall Inflammation in Patients with Active Rheumatoid Arthritis As Measured By an 18F-FDG-PET/CT Scan

Abstract Number: 355

Increased Left Ventricular Mass Index and Decreased Ejection Fraction Are Associated with Disease Activity in Rheumatoid Arthritis Patients without Cardiac Symptoms; Comparison Between Non-Biologic and Biologic Dmards Treatment Groups, Using a Cardiac Magnetic Resonance Imaging

Abstract Number: 356

The Rheumatoid Arthritis Impact of Disease Score Is Associated with Disease Activity By Clinical, Laboratory and Ultrasonographic Measures: Validation in an inception Cohort of DMARD naïve Patients with Rheumatoid Arthritis

Abstract Number: 357

Development and Validation of a Diagnostic Bead-Based Multiplex Autoantibody Assay:Screening for Autoantibodies to Detect “Seronegative” Rheumatoid Arthritis

Abstract Number: 358

Parity and Severity of ACPA-Positive/Negative Rheumatoid Arthritis. Results from the Swedish EIRA Study

Abstract Number: 359

14-3-3η Cit:Arg Antibody Ratios:  Are We Overlooking the Prognostic Utility of Citrullinated Antibodies By Only Looking at Titers?

Abstract Number: 360

88% of Recent Onset Polyarthritis Patients Are Positive for 14-3-3η Markers and 14-3-3η Auto-Antibodies Inform a Favourable Prognosis

Abstract Number: 361

Citrullinated 14-3-3η Antibodies Are Specific for Early and Established RA and Are Complementary to ACPA

Abstract Number: 362

14-3-3η Early RA Biomarkers: Does Seronegative RA Exist?

Abstract Number: 363

Increased Prevalence of Plasma Anti-Nuclear, Anti-SSA, and Connective Tissue Disease Associated Antibodies in African American Patients with Rheumatoid Arthritis

Abstract Number: 364

In Early Rheumatoid Arthritis, the Multi-Biomarker Disease Activity Score at Different Time-Points Is Predictive of Subsequent Radiographic Progression

Abstract Number: 365

Differential Relative Contribution of Individual Components on DAS28 over Time: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada

Abstract Number: 366

Soluble 4-1BB Is a Marker of Joint Involvement and Disease Activity in Rheumatoid Arthritis

Abstract Number: 367

In Early Rheumatoid Arthritis Patients with Non-Response to Methotrexate Monotherapy the Change in Multi-Biomarker Disease Activity Score Is Differentially Associated with Subsequent Response to Non-Biological Versus Biological Therapy

Abstract Number: 368

Serum C1M Level Predicts Disease Progression and Early Treatment Efficacy in Rheumatoid Arthritis

Abstract Number: 369

Validation of Snapshot, a Rheumatoid Arthritis Assessment Tool, Against CDAI, DAS28 (ESR), and DAS28 (CRP)  in Canadian Patients with Rheumatoid Arthritis

Abstract Number: 370

Double Positivity of RA Serologies More Prevalent Yet Associated with Clinical Response in Ethnic Minority Patients with Rheumatoid Arthritis

Abstract Number: 371

The Impact of Missing Anti-Citrullinated Protein Antibody (ACPA) on Outcomes in Early Rheumatoid Arthritis: From the Canadian Early Arthritis Cohort

Abstract Number: 372

Diagnostic Accuracy and Associated Costs of Rheumatoid Factor Testing in Primary Care: A Population-Based Cohort Study in Spain

Abstract Number: 373

Biomarkers of Cardiac Dysfunction and Inflammation in Plasma Predict Occult Coronary Plaque Burden and Composition in Rheumatoid Arthritis

Abstract Number: 374

IL-33 and Soluble ST2 Levels As Novel Predictors for Remission and Progression of Carotid Plaque in Early Rheumatoid Arthritis: A Prospective Study

Abstract Number: 375

Evaluation of RAPID3 with Minimal Joint Count and ACR/EULAR Provisional Remission Definitions As Predictors of Future Good Radiographic + Functional Outcome in a Double-Blind, Phase 3, Randomized Controlled Trial of Tocilizumab

Abstract Number: 376

Using the Multi-Biomarker Disease Activity Score As a Complementary Inclusion Criterion for Clinical Trials in Rheumatoid Arthritis May Enhance Recruitment

Abstract Number: 377

Fatigue Fluctuates Substantially over Time in Rheumatoid Arthritis Patients Despite Stable Disease Activity during Treatment with Biological Agents

Abstract Number: 378

The Use of Week 12 CDAI, RAPID3 and DAS28(CRP) Responses to Predict Optimal Response to Methotrexate

Abstract Number: 379

What Level of Disease Activity at 6 Months Predicts Achieving or Sustaining Remission at 12 Months?

Abstract Number: 380

In Palindromic Rheumatism, Older Age, Shorter Interval Between Attacks and Positive Anti-CCP Antibodies May Predict Progression to RA

Abstract Number: 381

Distribution and Clinical Significance of Anti-Heterogenic Nuclear Ribonucleoprotein A2 Antibody in Connective Tissue Diseases

Abstract Number: 382

What Is More Predictive of Achieving Remission at 12 Months: The Percentage of Baseline Improvement or the Actual Disease State Achieved at 6 Months?

Abstract Number: 383

How Low Is Low Disease Activity? an Analysis from a Prospective, Observational Registry

Abstract Number: 384

Using Patient Reported Outcome Measures to Classify Disease Activity States in Rheumatoid Arthritis: A Comparison of Patient Activity Score (PAS) and Routine Assessment of Patient Index Data (RAPID)

Abstract Number: 385

Validation of a Prognostic Model to Predict Structural Damage Assessed By X-Ray in Patients with RA Using MRI Data from a Clinical Trial

Abstract Number: 386

Association of Pharmacogenetic Markers with Treatment Response in Patients with Rheumatoid Arthritis

Abstract Number: 387

Levels of IgG Autoantibodies to Oxidation-Associated MDA Neo-Determinants Are a Biomarker for Systemic Inflammation and Disease Activity in SLE and RA

Abstract Number: 388

Soluble TREM-1 Is a Biomarker of Anti-CCP-Positive, DMARD-Naive Early Rheumatoid Arthritis

Abstract Number: 389

High 11B-HSD1 Activity Is Associated with Progression to Rheumatoid Arthritis in Patients with a New Onset of Inflammatory Arthritis

Abstract Number: 390

Prevalence and Correlates of Patient-Physician Discordance in Early Rheumatoid Arthritis

Abstract Number: 391

Self-Assessment Tool of Rheumatoid Arthritis Disease Activity: Handgrip Strength Measured By a Smartphone Connected to a Dynamometer

Abstract Number: 392

Neuroendocrine Hormone and Metabolic Peptide Levels in the Earliest Phases of Rheumatoid Arthritis – Do Free Fatty Acids Play a Role?

Abstract Number: 393

Influence of Body Mass Index on Disease Activity and Radiographic Joint Damage in Rheumatoid Arthritis : A Systematic Review and Meta-Analysis

Abstract Number: 394

Very Low or High Body Mass Index Negatively Affects patients’ Ability to Achieve Sustained Remission in Early RA in a Multicenter Canadian Cohort

Abstract Number: 395

Could Osteoprotegerin and TNF-Related Apoptosis-Inducing Ligand Assessments Help Us to Manage Early Rheumatoid Arthritis? Results from the Espoir Cohort

Abstract Number: 396

Disease Activity Scoring: Comparing Patient and Physician Global Assessment of Disease Activity in Rheumatoid Arthritis

Abstract Number: 397

Th9 Lymphocytes in Rheumatoid Arthritis

Abstract Number: 398

Anti-Rheumatic Therapy Decreases Syndecan-1 Shedding in Rheumatoid Arthritis (RA)

Abstract Number: 399

Lipid Concentrations and Particle Sizes in Drug Naive Patients with Rheumatoid Arthritis

Abstract Number: 400

Clinical Utility of 14-3-3η in the Evaluation of Inflammatory Arthritis

Abstract Number: 401

Association of Anti-Thyroid Autoantibodies with Fibromyalgia in Rheumatoid Arthritis

Abstract Number: 402

Can GP88 (Progranulin) be Used As a Biomarker for the Diagnosis and Therapy Evaluation of Rheumatoid Arthritis?

Abstract Number: 403

Metaflammation, PEDF and Chemerin: Potential Systemic Factors Which Link Obesity to Response to Therapy in Early Rheumatoid Arthritis

Abstract Number: 404

The Relationship Between Disease Activity and Levels of HMGB1 in Patients with Rheumatoid Arthritis

Abstract Number: 405

14-3-3η: A Mechanistic Biomarker That Supports the Concept of “Uncoupling” of Inflammation and Joint Damage

Abstract Number: 406

The Utility of HLA-DR Genotypification As a Complementary Tool to Discriminate Undifferentiated and Rheumatoid Arthritis Patients in Early Arthritis

Abstract Number: 407

Serum 14-3-3η Protein Supplements Traditional Rheumatoid Arthritis Biomarkers

Abstract Number: 408

14-3-3η Auto-Antibody Positivity Informs Better Clinical Outcomes in RA

Abstract Number: 409

Soluble CD163 Is a Marker of Disease Activity in Early Rheumatoid Arthritis and Reflects TNFα Levels

Abstract Number: 410

Vascular Endothelial Function Changes during Treatment in Patients with Rheumatoid Arthritis

Abstract Number: 411

ABCB1 and ABCG2 Drug-Efflux Transporters Function and Its Association with Disease Activity in a Cohort of Patients with Rheumatoid Arthritis

Abstract Number: 412

Determinants of Radiological Progression in Rheumatoid Arthritis: Relationship with Serum Levels of OPG, RANKL and DKK-1

Abstract Number: 413

Association of Antinuclear Antibodies with Lung Disease, Malignancy and Joint Replacement in Rheumatoid Arthritis

Abstract Number: 414

Relationship Between Range of Motion of Joints in Upper Limbs and Physical Function in Patients with Long-Standing Rheumatoid Arthritis: Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Physical Function

Abstract Number: 415

a Dual-Center, Double Blind Randomized Study for a New Scientific Approach in Assessment of Tender Joints in Inflammatory Arthritis Using the Smart Joint Assessor Glove Device (Smart JAG Device)

Abstract Number: 416

Using Patient Reported Outcome Measures to Classify Disease Activity States in Rheumatoid Arthritis: A Comparison of Patient-Derived Versions of Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI) and Disease Activity Score 28 (DAS28)

Abstract Number: 417

Normal Scores of “0” (floor effects) Are Seen in 33-83% of Patients with Rheumatoid Arthritis (RA) on 8 HAQ Activities Which Also Are Found on the MDHAQ, but in Fewer Than 32% of Patients on 2 Unique MDHAQ Complex Activities “Walk 2 Miles or 3 Kilometers,” and “Participate in Recreation and Sports.”

Abstract Number: 418

Prevalence of Morning Stiffness in a US Registry Population of Rheumatoid Arthritis Patients

Abstract Number: 419

Comparative Dynamics of Rheumatoid Arthritis Disease Activity and Disease Severity Measures Using Rarbis, Ciras and DAS28 in a Population Based Cohort of Patients with RA

Abstract Number: 420

Less Is More: The Shorter Physical Function Measure Promis-PF10a Outperforms HAQ in an Ethnically Diverse, Urban Rheumatoid Arthritis Clinic Population

Abstract Number: 421

Prediction of Remission By Patients and Physicians: Does the Doctor Know Best?

Abstract Number: 422

Correlation of RAPID3, DAS28 and CDAI in Disease Activity and Effects of Education Level and Co-Morbid Diseases on This Assesment in RA

Abstract Number: 423

Circulating Anti-Citrullinated Peptide Antibodies and Cytokines As Biomarkers of Response to Disease-Modifying Antirheumatic Drugs Therapy in Early Rheumatoid Arthritis

Abstract Number: 424

The Comparison Between Physical and Ultrasound Joint Examination for the Hand Joints in Patients with Rheumatoid Arthritis

Abstract Number: 425

Beyond Disease Activity: Patient Global Scores Also Reflect Treatment Expectations and Emotional Reactions to Living with Rheumatoid Arthritis

Abstract Number: 426

Exploring the DAS: What Is the Level of Agreement in the Classification of Remission and Low Disease Activity (LDA) Among the Various Versions of the Disease Activity Score (DAS) and Their Correlation? an Analysis from a Prospective, Observational Registry

Abstract Number: 427

Multimedia Patient Education Tool for Patients with Rheumatoid Arthritis

Abstract Number: 428

Patient-Physician Discordance of Disease Activity Assessments Predicts Inadequate Treatment Response in Early Rheumatoid Arthritis

Abstract Number: 429

Investigation of MRI Bone Changes in Early-Stage RA Patients Achieved in Sustained Clinical Good Response: Sub-Analysis from Nagasaki University Early Arthritis Cohort

Abstract Number: 430

Minimally Important Difference in the European Quality of Life-Five Dimensions in Patients with Rheumatoid Arthritis

Abstract Number: 431

Joint Dermal Temperature Specifically Identifies the Individual RA Patient Most Likely to Develop Radiographic Change on Sharp Score; An Exam in Less Than a Minute Can Predict Who Specifically Needs Biologic Therapy

Abstract Number: 432

Rheumatoid Arthritis-Associated Interstitial Lung Disease: Risk Factors for Disease Progression